Helius Medical Technologies Inc Class A

NASDAQ HSDT

Download Data

Helius Medical Technologies Inc Class A Enterprise Value to EBITDA (EV/EBITDA) on June 03, 2024

Helius Medical Technologies Inc Class A Enterprise Value to EBITDA (EV/EBITDA) is NA on June 03, 2024, a NA change year over year. The EV/EBITDA ratio compares a company's enterprise value to its EBITDA. It provides insight into the company's valuation relative to its earnings and is commonly used in comparing the relative value of different companies within an industry. A lower ratio suggests a potentially more favorable valuation.
  • Helius Medical Technologies Inc Class A 52-week high Enterprise Value to EBITDA (EV/EBITDA) is NA on June 03, 2024, which is NA below the current Enterprise Value to EBITDA (EV/EBITDA).
  • Helius Medical Technologies Inc Class A 52-week low Enterprise Value to EBITDA (EV/EBITDA) is NA on June 03, 2024, which is NA below the current Enterprise Value to EBITDA (EV/EBITDA).
  • Helius Medical Technologies Inc Class A average Enterprise Value to EBITDA (EV/EBITDA) for the last 52 weeks is NA.
NASDAQ: HSDT

Helius Medical Technologies Inc Class A

CEO Mr. Dane Carl Andreeff
IPO Date June 27, 2014
Location United States
Headquarters 642 Newtown Yardley Road, Newtown, PA, United States, 18940
Employees 22
Sector Healthcare
Industry Medical devices
Description

Helius Medical Technologies, Inc., a neurotechnology company, focuses on developing, licensing, and acquiring non-implantable technologies for the treatment of symptoms caused by neurological disease or trauma. The company's product is Portable Neuromodulation Stimulator, a non-surgical medical device intended for use as a short term treatment of gait deficit due to symptoms from multiple sclerosis and balance deficit due to mild-to-moderate traumatic brain injury, as well as to be used in conjunction with supervised therapeutic exercise. Helius Medical Technologies, Inc. was incorporated in 2014 and is headquartered in Newtown, Pennsylvania.

StockViz Staff

September 16, 2024

Any question? Send us an email